Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BALANCE-II
- Sponsors AbbVie
- 14 Oct 2019 Results of exposure response analysis of upadacitinib using data from Phase 2 and Phase 3 rheumatoid arthritis (RA) studies published in the Clinical Pharmacology and Therapeutics
- 15 Jun 2019 Results evaluating the effect of Upadacitinib treatment on cholesterol efflux capacity (CEC) from a subset of patients from the Phase 2 BALANCE II study 2 and the Phase 3 SELECT-NEXT study, are presented at the 20th Annual Congress of the European League Against Rheumatism
- 13 Jun 2019 Results of exposue response analysis of Upadacitinib efficacy in phase 2 trials (BALANCE-I and BALANCE-II) published in the Clinical Pharmacology and Therapeutics